InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Saturday. The brokerage issued a sell rating on the stock.

InspireMD Price Performance

NSPR stock opened at $2.80 on Friday. The company has a market capitalization of $69.80 million, a P/E ratio of -3.68 and a beta of 0.90. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.85. The firm’s fifty day simple moving average is $2.74 and its 200-day simple moving average is $2.51.

InspireMD (NYSE:NSPR) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The business had revenue of $1.74 million during the quarter, compared to analysts’ expectations of $1.74 million. InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. During the same period in the previous year, the company posted ($0.24) earnings per share. As a group, sell-side analysts forecast that InspireMD will post -0.82 earnings per share for the current year.

Institutional Trading of InspireMD

A number of hedge funds have recently added to or reduced their stakes in the company. McKinley Carter Wealth Services Inc. purchased a new stake in InspireMD in the 4th quarter worth $28,000. Mesirow Financial Investment Management Inc. purchased a new stake in shares of InspireMD during the first quarter worth about $71,000. Finally, Rosalind Advisors Inc. raised its position in shares of InspireMD by 266.4% during the 2nd quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock worth $6,272,000 after purchasing an additional 1,827,579 shares during the last quarter. 44.78% of the stock is owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.